PDB41 COST-UTILITY OF INSULIN GLARGINE IN COMBINATION THERAPY WITH ORAL AGENTS COMPARED WITH PREMIX INSULIN WITH OR WITHOUT OF ORAL AGENTS IN TYPE 2 DIABETES. THE POLISH PERSPECTIVE
Abstract
Authors
M Dziewiatka K Kostrzewska J Krzystek D Wilk M Wladysiuk J Lis R Plisko P Rys